

Leptin augmented model to include the role of obesity in insulin-glucose regulatory system for T2DM subjects

Manoja Rajalakshmi Aravindakshan^{1*}, Devleena Ghosh¹, Chittaranjan Mandal¹, Jit Sarkar², Sujay K Maity² and Partha Chakrabarti²

^{1*}Department of Computer Science and Engineering, Indian Institute of Technology, West Bengal 721302, India.

²Division of Cell Biology and Physiology, Indian Institute of Chemical Biology, West Bengal 700032, India.

*Corresponding author(s). E-mail(s): manojalax@gmail.com;
Contributing authors: devleenaghosh07@gmail.com;
chitta@iitkgp.ac.in; jitnpur@gmail.com;
maity Sujaykrishna@gmail.com; partha.iicb@gmail.com;

Abstract

Leptin is a fat cell-derived hormone involved in satiety and body weight regulation. It also plays a critical regulatory role in the insulin-glucose regulatory system by modulating glucose metabolism and energy homeostasis. However, existing insulin-glucose models often fail to consider the impact of body weight indicators mainly body mass index (BMI) and plasma leptin. To address this limitation, we propose augmenting the ordinary differential equations (ODE) of the Oral Minimal Model (OMM) with an additional equation, incorporating leptin as well as supplementary terms and parameters. By estimating the model parameters, the model behaviour is aligned with the observed data of glucose, insulin and leptin for individuals with type 2 diabetes mellitus (T2DM). Based on model behaviour, revised indices formulated from Oral Glucose Tolerance Test (OGTT) data by including BMI and fasting leptin values are found to have a better correlation with existing indices. Additionally, parameter sensitivity analysis is performed to investigate the influence of the model parameters on the observed variables. Validation of the augmented model with clinical data (without leptin) demonstrates a superior fit to glucose

and insulin data compared to the base model. This model emphasizes the intricate associations between leptin, glucose, and insulin concentrations with a potential for developing targeted interventions and therapies for T2DM. Notably, this manuscript introduces the first ODE-based model that incorporates leptin and BMI in the insulin-glucose pathway.

Keywords: Leptin model, oral minimal model, OGTT, mathematical modelling, parameter estimation, sensitivity analysis

1 Introduction

Insulin glucose (IG) regulatory system is a biochemical system that helps to maintain a steady glucose level in the blood. The main source of glucose is from meal ingestion (exogenous input) and excess glucose is converted to glycogen by the liver and stored there. When the level of glucose falls in the blood (due to exercise or a long gap after the last meal), pancreatic α -cells secrete glucagon to release glucose (glycogenolysis) from the liver through the breakdown of glycogen until the glucose level rises to normal. When the level of glucose rises in the blood (after a meal), pancreatic β -cells secrete insulin to trigger the uptake of glucose by the peripheral tissue cells in the body until the glucose level falls back to normal. Type-2 diabetes mellitus (T2DM) occurs when the body becomes resistant to the effects of insulin and the pancreas fails to produce enough insulin to compensate for this resistance [1]. Excess body fat (obesity), particularly abdominal or visceral fat, is associated with insulin resistance (IR), a condition in which the cells of the body become less responsive to insulin. This reduced sensitivity to insulin leads to elevated blood glucose levels resulting in the characteristic symptoms and complications of T2DM [1]. Obesity-induced IR is followed by β -cell dysfunction leading to T2DM, however, the contribution of obesity and β -cell dysfunction in T2DM development vary significantly among the non-obese and obese population [2, 3].

Obesity is a major risk factor for the development of T2DM[4]. Leptin, a hormone secreted by fat cells, plays a crucial role in regulating body weight and energy balance. Leptin acts on the hypothalamus to suppress appetite and increase energy expenditure [5]. Additionally, leptin has various secondary functions in peripheral tissues, wherein it influences insulin level and glucose metabolism in the body. In the relationship analysis between leptin and body mass, serum leptin concentration is found to have a direct positive association with body mass index (BMI) [6]

There are several theoretical works [7, 8] that emphasize the role of leptin in IR and its importance in T2DM. Mathematical models including leptin in diet and type 1 diabetes [9–11] exist with numerical simulation results, however, we aim for a model for T2DM that can capture leptin behavior using OGTT data. Our objective is to not only conceptualize such a model but to substantiate its real-world relevance through rigorous validation using clinical data.

This is achieved by augmenting the Oral Minimal Model (OMM) proposed by Dallaman et al. [12, 13] to include the role of leptin and BMI. Our model aims to incorporate the regulatory influence of leptin on insulin-glucose dynamics, thereby improving the existing model fitting of glucose and insulin data and accurately capturing the leptin data. Consistent with the OMM approach, the current model uses clinical data derived from the Oral Glucose Tolerance Test (OGTT) for parameter estimation and analysis.

OGTT is a frequently used diagnostic test in which the subject's fasting blood glucose levels are measured, followed by the ingestion of a specific amount of glucose dissolved in water, and subsequently, blood is collected at regular intervals to measure glucose and insulin levels at varying intervals [14]. It is a highly sensitive test used for screening and diagnosis of T2DM. The dataset used for modeling in the current work consists of data of individuals who have undergone a 2-hour OGTT. In addition to insulin and glucose, leptin concentrations are also taken at various time points for this study. OGTT indices (derived from OGTT data) are quantitative measures that provide information about the subject's insulin sensitivity, β -cell function, and overall glucose regulation in response to a glucose load. The current work attempts to suggest modifications and enhancements to selected OGTT indices.

One of the crucial aspects of modeling is to understand how parameter values change with model output. The parameter variations affect the output of a model when dealing with critical data specific to biochemical pathways. The interpretation of parameter values in these pathways is important to understand the relationship to their physiological properties. Sensitivity analysis on the augmented model is also conducted to explore the behaviour of model parameters, providing inference on the model's outcomes. Additionally, validation of the model is performed using a different dataset, as detailed in the subsequent sections. The present study introduces a novel approach to modelling the interaction between leptin and the insulin-glucose pathway, which has not been previously explored in the existing literature. The following sections describe the background, augmented model and parameter estimation followed by results and discussion.

2 Background

ODE modelling started with the *minimal model* for modelling the intravenous glucose tolerance test (IVGTT). Bergman's minimal model is a well-accepted coupled model from the original model [15]. The simplest form of OMM [12] as ordinary differential equations (ODE) are represented in Eqn. 1:

$$\begin{aligned}\frac{dG}{dt} &= -k_1 \cdot (G - G_b) - X \cdot G + \frac{R_a(t)}{V} \\ \frac{dX}{dt} &= -k_2 \cdot X + k_3 \cdot (I - I_b) \\ \frac{dI}{dt} &= \gamma \cdot (G - G_T)^+ - k_4 \cdot I\end{aligned}\tag{1}$$

where G , I denotes blood glucose concentration and blood insulin concentration (suffix b denotes basal values) at time t , respectively. Here, X is an auxiliary variable to model the time delay in insulin-dependent glucose uptake activity. The initial values of G and I are taken at the time when the glucose is orally ingested. The initial value of X is taken as 0 and $(G - G_T)^+ = (G - G_T)$, if $G > G_T$ and 0 otherwise. R_a is the rate of absorption of ingested glucose; V is the volume of distribution; k_1 is the fractional glucose effectiveness i.e., the ability to promote glucose disposal and inhibit glucose production, k_2 is the insulin-dependent increase in glucose uptake ability in tissue per unit of insulin concentration above I_b , k_3 is a scale factor for the amplitude of insulin action and k_4 is the first-order decay rate for insulin in plasma. There are several complex IG models that have evolved over time ([16, 17]). The OMM is based on the Bergman minimal model [15] in which the glucose analysis is done using IVGTT. The variable X in the minimal model could be more accurately understood as representing the incremental insulin response within the interstitial space in response to a bolus stimulus, rather than being directly proportional to the interstitial insulin level, as it was conventionally assumed [18]. A quantitative physiological model for insulin glucose regulatory system will be more suitable for epidemiological studies and this is achieved in the OMM developed by Dallaman et al. [12] based on OGTT. The model presented in this paper is based on the well-cited work of Dallaman et al. [12, 19] on the OMM.

The rate of appearance of oral glucose in plasma is coupled with minimal model of glucose kinetics through the parameter R_a . The Model-2 in the work of Man et al. [13], hereafter referred to as R_a model, is used in the current work with a modification, which is in accordance with the non-linear gastric emptying of glucose (liquid phase). The solid phase glucose compartment from the stomach is removed as it deals with a grinding rate parameter which is not relevant to our study as glucose solution is orally ingested. The R_a model equations are given as follows (Eqn. 2):

$$\begin{aligned} \frac{q_{sto}}{dt} &= -k_{empt} \cdot q_{sto}(t) + D \cdot \delta(t) \\ \frac{q_{gut}}{dt} &= -k_{abs} \cdot q_{gut}(t) + k_{empt} \cdot q_{sto}(t) \\ R_a(t) &= f \cdot k_{abs} \cdot q_{gut}(t) \end{aligned} \quad (2)$$

where q_{sto} is the amount of glucose in the stomach, $\delta(t)$ is the impulse function, D is the amount of ingested glucose, q_{gut} is the glucose mass in the intestine, k_{empt} is the rate of gastric emptying and is a function of q_{sto} [13], k_{abs} is the rate constant of intestinal absorption, and f is the fraction of the intestinal absorption which actually appears in plasma. This model with ODEs of OMM (Eqn. 1) is considered as *base* model from hereon.

By efficiently integrating BMI and the adipokine leptin into the existing OMM, their associations with insulin and glucose concentrations can be

effectively modelled. Leptin is associated with insulin resistance and is positively correlated with BMI [20]. Leptin decreases insulin secretion to a certain extent [21] and also exhibits a negative correlation with fasting plasma glucose and postprandial glucose after two hours. Leptin also decreases hepatic glucose production, increases insulin sensitivity, and decreases glucagon levels. This inhibitory action of leptin is modelled using enzyme kinetics in this work. Insulin, in turn, also plays a role in stimulating leptin production and secretion in the adipose tissue [7]. Leptin deficiency results in impaired glucose metabolism and prolonged insulin resistance [8].

The commonly used indices to access beta cell function and insulin resistance are briefly explained here. HOMA-B (Homeostatic Model Assessment of Beta-Cell Function) is a mathematical model used to estimate β -cell function based on fasting glucose and fasting insulin levels, particularly in the context of insulin resistance and T2DM. The formula for calculating HOMA-B is $\left(\frac{I_0 - 20}{G_0 - 3.5}\right)$, where I_0 is fasting insulin (in $\mu U/mL$) and G_0 is fasting glucose (in $mmol/L$) values. HOMA2 is an improvement over the original HOMA model, as it considers glucose dynamics across populations and different physiological states. Several software tools that accurately calculate HOMA2 values use advanced algorithms as in the HOMA calculator [22] provided by the diabetes trials unit at the University of Oxford. HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a widely used method for estimating insulin resistance, which is a key component of various metabolic disorders, including T2DM. The formula for calculating HOMA-IR is $\left(\frac{I_0 \cdot G_0}{22.5}\right)$, where I_0 is in $\mu U/mL$ and G_0 is in $mmol/L$.

The insulin sensitivity index (ISI) is derived from the concept that insulin sensitivity can be assessed by evaluating the ability of insulin to regulate glucose levels. The formula for calculating ISI is $\left(\frac{\Delta I_{0-30}}{\Delta G_{0-30}}\right)$, where Δ is difference in fasting and 30 min values of insulin(I) and glucose(G). Higher ISI values indicate greater insulin sensitivity, meaning that the cells in the body are more responsive to insulin and effectively utilize glucose. The oral disposition index, DI_o [23] calculated as $\left(\frac{\Delta I_{0-30}}{\Delta G_{0-30}}\right) \cdot \left(\frac{1}{I_0}\right)$, where I_0 is in $pmol/L$ and G_0 is in $mmol/L$, is commonly used as a measure of β -cell function.

The idea of parameter estimation is to find unknown parameters in a computational model which may describe the given biophysical pathway or phenomenon. These unknown parameters are estimated using experimental data which are collected from well-defined and standard conditions by minimizing the error between the model simulations results and experimentally known data [24]. This way the behaviour of the model is captured effectively. The challenge is that no single optimal estimation technique exists for all models. Many different estimation methods have been developed so far to determine the best strategy for a given problem. The commonly used parameter estimation methods include maximum likelihood estimation [25] and Nelder

Mead optimization [26]. Nelder Mead method is a numerical method in non-linear optimisation problems to find the minima of objective functions. Least square estimation is used in regression models and maximum likelihood estimation is used in statistical models [27]. In addition evolutionary methods [28] namely genetic algorithms and particle swarm optimization are other efficient parameter estimation methods used in non-linear dynamic models.

Our aim is to develop an underlying well-established model that includes the role of BMI and leptin by estimating the set of parameters that are significant.

3 Augmented model

Leptin level plays a major role in glucose homeostasis and is positively correlated with adiposity. In the presence of high blood glucose levels, leptin enhances tissue glucose uptake, independent of insulin, and reduces hepatic glucose production [7]. Leptin has glucose-lowering effects via an insulin-independent mechanism which normalizes hepatic glucose production and increases glucose uptake in peripheral tissues including adipose tissue, muscle and heart [29]. Insulin promotes adipogenesis (formation of fat cells from pre-adipocytes) and increases body fat mass [30]. It also stimulates the production and release of leptin, which acts centrally to decrease food intake and boost energy expenditure. Leptin, in turn, inhibits insulin secretion through both central and direct effects on β -cells. As plasma leptin level is directly linked to body fat mass, higher adiposity raises plasma leptin, thereby reducing insulin production and promoting further increasing fat mass [31] (Fig. 5). In this way, both leptin and insulin regulate each other, sharing the control of food intake and metabolism [7].

BMI which is a measure of body fat, is based on the weight and height of an adult. Adipose tissue produces leptin in quantities proportional to its mass and thereby regulates body weight. Moreover since leptin level increases with BMI [32] we have modelled the regulatory role of leptin and BMI in the IG regulatory system by augmenting the oral minimal model.

The augmentations carried out in the OMM are as follows:

- leptin-induced glucose absorption in peripheral tissues independent of insulin [5, 33],
- leptin-induced inhibition of insulin secretion [7],
- leptin production from adipose tissue modelled through BMI. This production can be dependent and independent of insulin [6, 7].

For accommodating leptin concentration, one additional differential equation (DE, Eqn. 7) is added and additional terms ($T_1 - T_6$) in the DEs for glucose and insulin concentrations (Eqns. 3, 5) are added. Also, an expression (Eqn. 6) for capturing the effect of BMI is introduced. The augmented model




Fig. 1: *Leptin* model: The augmentations to the model are visually highlighted using the colour green. Leptin has glucose-lowering effects independent of insulin. Insulin increases the production of leptin by adipose tissue (fat cells). Leptin feeds back to reduce insulin secretion.

equations are given as follows:

$$\frac{dG}{dt} = k_1 \cdot G_b - \left(k_1 + X + \underbrace{g_l \cdot L}_{T_1} \right) \cdot G + \frac{R_a(t)}{V} \quad (3)$$

$$\frac{dX}{dt} = k_3 \cdot (I - I_b) - k_2 \cdot X \quad (4)$$

$$\frac{dI}{dt} = \underbrace{\frac{\gamma}{(1 + k_6 \cdot L)}}_{T_2} \cdot (G - G_T)^+ - k_4 \cdot I \quad (5)$$

$$k_{\text{BMI}} = \underbrace{\frac{1}{1 + e^{-\frac{\text{BMI}}{b_m}}}}_{T_3} \quad (6)$$

$$\frac{dL}{dt} = k_{\text{BMI}} \cdot \left(\underbrace{k_b}_{T_4} + \underbrace{\frac{k_i \cdot I}{k_l + I}}_{T_5} \right) - \underbrace{k_5 \cdot L}_{T_6} \quad (7)$$

where L is the leptin concentration in the blood, BMI is the body mass index of the subject, g_l denotes the ability of leptin to lower blood glucose levels, k_6 denotes the inhibitory action of leptin on insulin, b_m is a scaling factor that regulates the effect of BMI, k_b is the BMI contribution factor to leptin production, k_i denotes leptin production based on insulin, k_l denotes the ability of insulin to stimulate leptin production and k_5 is the leptin degradation rate.

The ability of leptin to independently lower blood glucose levels is modelled as T_1 in Eqn. 3. The effect is coupled with glucose as there exists a co-regulation between leptin and glucose via insulin. As leptin inhibits insulin production [21], this behaviour is modelled assuming reversible competitive inhibition [34] as T_2 in Eqn. 5. The role of BMI in leptin production is modelled empirically as a logistic function (Eqn. 6) to incorporate the behaviour of leptin for the BMI range of [18, 40]; the parameters are determined through regression using dataset-1. An additional equation for leptin concentration (Eqn. 7) is added by introducing the effect of BMI and insulin in leptin production and a decay term to model the degradation of leptin over time. The basal level of leptin is handled in the model using the term T_4 in the Eqn. 7 for leptin k_{BMI} is a function of BMI that regulates the effect of BMI in leptin concentration with a scaling parameter b_m . As leptin is mainly produced from body fat this effect is introduced by the term $k_{BMI} \cdot k_b$, as BMI increases the effect of this term in leptin production also increases. The positive correlation of insulin in leptin concentration is modelled following Michaelis–Menten (MM) kinetics (represented as T_5). The term T_6 models leptin degradation. The newly introduced model parameters and some of the existing parameters are estimated using available data. This model (Eqns. 3-7) is considered as *leptin* model in this paper.

4 Parameter Estimation

The parameters of the augmented model are estimated using the dataset described in section 4.1. Seven new parameters - $g_l, k_l, k_b, b_m, k_5, k_6$ and k_i are introduced in the augmented model. Model fitting is done to minimise the error between the observed data and simulated behavior of the model.

4.1 Dataset used for parameter estimation

Two sets of data are used in the study. Dataset-I consists of 40 rows of data related to subjects with T2DM, collected from a community-based primary health clinic located in the district of North 24 Parganas of West Bengal, India, who underwent OGTT. After pre-processing (removal of rows with missing values) the dataset consisted of data from 38 subjects. The subjects were asked to ingest 75g of glucose dissolved in 100mL of water after fasting for 8-12 hours. The sample rows from dataset-I are shown in Table 1a. The dataset consists of the following columns: BMI, measurements of insulin, glucose and leptin at various time points. FGLU indicates fasting glucose level. $GLU\langle t \rangle$, $INS\langle t \rangle$ and $LEP\langle t \rangle$ indicate glucose, insulin and leptin levels after time $\langle t \rangle$ of orally

Code	BMI	FINS	INS15	INS120	FGLU	GLU15	GLU120	FLEP	LEP15	LEP120
DM-06	28.5	0.68	2.22	9.48	289.57	313.60	485.08	36.03	27.54	57.01
DM-08	25.2	0.17	9.24	16.32	177.87	197.92	404.95	10.53	4.66	4.99
DM-28	26.4	1.93	2.98	58.35	145.17	182.76	420.99	30.24	11.75	13.33
DM-34	23.8	0.64	0.46	6.38	167.80	192.50	400.69	8.40	9.82	2.65

(a) Dataset-I

Code	FGLU	GLU15	GLU30	GLU90	GLU120	FINS	INS15	INS30	INS60	INS120
S1	202.5	237	279	384	385.02	90	200	220	300	300
S2	195.48	263	314	419	419.04	18	13	21	42	38
S3	120.96	154	232	364	383.94	7	21	30	69	70
S4	148.50	194	249	376	334.08	40	33	90	190	140
S5	256.50	299	320	455	466.02	6.5	13	24	31	38

(b) Dataset-II

Table 1: Sample rows from dataset-I and dataset-II. Glucose units are in mg/dL and insulin units are in $\mu U/mL$ and

ingesting glucose beyond fasting glucose measurement (at $t = 0$), respectively. For example, GLU30 indicates glucose level after 30 min and LEP45 indicates leptin level after 45 min. The measurements are taken at times: 0, 15, 30, 45, 60, 75, 90, and 120 minutes. All participants gave informed consent and the study was approved by the Institutional Human Ethics Committee of CSIR-IICB.

Dataset-II consists of OGTT data of 129 individuals diagnosed with T2DM, collected from local pathology labs by a collaborator from a research institute. The subjects were asked to ingest 25g of glucose dissolved in 100mL of water after fasting for 8-12 hours. Sample data from dataset-I are given in Table 1b. The column names are similar to dataset-I with only changes in time points. The measurements in dataset-II are taken at times: 0, 15, 30, 60, 90, and 120 minutes. These data were obtained from local pathology laboratories in anonymized form, ensuring the protection of patient confidentiality. The dataset-I is used for estimation of parameters in the leptin model and dataset-II is used in validation of the model.

The condition which is characterized by abnormally high levels of insulin in the bloodstream (hyperinsulinemia) strongly influences leptin levels [6]. This is not accommodated in the present model as the available data used in the study only included subjects who were not affected by hyperinsulinemia.

4.2 Estimation Techniques

Parameter estimation is performed by solving an optimisation problem to minimise the squared error between outputs obtained from solving ODE and the observed data. The methods are implemented and coded in Python framework using the SciPy packages `odeint()` [36] and `lmfit()` [37]. Parameter estimation runs were performed for each individual subject, and average parameter values were calculated from the estimated results. Different estimation techniques were tried out, and Nelder-Mead optimisation [26] gave a better fit of observed

Table 2: Estimated parameters in *leptin* model

Symbol	Description	Value	CV	Source	Unit
g_l	the ability of leptin to lower blood glucose levels	3.66	2.85	Estimated	$\frac{L \text{min}^{-1}}{\mu\text{mol}}$
k_l	ability of insulin to stimulate leptin production	4.99e-05	1.92	Estimated	min^{-1}
k_5	leptin degradation rate	0.03		Calculated from [35]	min^{-1}
k_6	the inhibitory action of leptin on insulin	749.74	2.80	Estimated	$L/\mu\text{mol}$
k_b	BMI contribution factor to leptin production	9.41e-05	0.89	Estimated	min^{-1}
k_i	leptin production based on insulin	5.15e-05	4.15	Estimated	min^{-1}
b_m	scaling factor that regulate effect of BMI	21		Calculated from Eqn. 6	constant
k_1	glucose effectiveness; the ability to promote glucose disposal and inhibit glucose production	0.027		Estimated	min^{-1}
k_2	the insulin-dependent increase in glucose uptake ability in tissue per unit of insulin concentration above I_b	0.110		Estimated	min^{-1}
k_3	scale factor for the amplitude of insulin action	7.634		Estimated	$\frac{\text{min}^{-2}}{(\mu\text{mol}/L)^{-1}}$
k_4	decay rate for insulin in plasma	3.349		Estimated	min^{-1}
γ	the rate of the pancreatic β -cells' release of insulin after the glucose injection and with glucose concentration above D	0.017e-6		Estimated from base model	$\mu\text{mol}/L$

data. The error function used in estimation is defined as follows:

$$E(\theta) = \sum_{i=1}^m (\hat{y}_i - y_i(\theta))^2 \quad (8)$$

where \hat{y}_i are observed data values and y_i are simulated values for a given parameter θ at m time points.

When performing parameter estimation or fitting for the system of ODEs, it is common to impose bounds on the parameters to ensure that the estimated values are within a reasonable and physiologically meaningful range. Setting parameter bounds helps to constrain the optimization process and prevents unrealistic or unbounded parameter estimates. This model considers parameter ranges reported in the relevant literature and physiological constraints while setting parameter bounds.

4.3 Parameter Sensitivity Analysis

Parameter sensitivity analysis is used to examine how sensitive a mathematical model responds to variations in its input variables. When every parameter in




Fig. 2: Sensitivity analysis of parameters with $\pm 30\%$ variation wrt glucose, insulin and leptin

an ODE model is varied to understand the model response, global sensitivity analysis is used. The general formulation of a non-linear dynamic system is shown as:

$$\dot{x} = f(x, t, p, u); y = g(x, t, p, u); x(0) = u$$

where $x \in \mathbb{R}^{n_s}$ is the vector of n_s number of state variables, $u \in \mathbb{R}^{n_u}$ is the vector of n_u number of initial values of state variables, $p \in \mathbb{R}^{n_p}$ is the parameter vector of length n_p and $y \in \mathbb{R}^{n_y}$ is the output vector of length n_y . The first-order sensitivity function is a sampling time dependent matrix $S_{it}(t_k)$ such that the sensitivity value of i^{th} output variable concerning j^{th} parameter at time t_k is defined as:

$$S_{it}(t_k) = \frac{\delta y_i(t_k)}{\delta p_j}$$

Parameter ranges for new parameters in the model are determined through sensitivity analysis. This is done by systematically varying the values of parameters within certain ranges and observing the impact on model behaviour. In this way, sensitivity analysis helps identify the ranges of parameter values that produce reasonable model responses constrained within physiologically plausible ranges.

5 Revision of indices derived from OGTT

Introducing a revised version of HOMA-B, HOMA2, and HOMA-IR, which incorporates BMI and fasting leptin, is a valuable approach to account for the influence of obesity on beta-cell function and insulin resistance. The resulting indices can provide a more comprehensive assessment of insulin secretion and sensitivity. HOMA-B focuses only on fasting glucose and insulin values, while DI_o also considers post-prandial values. The revised indices for HOMA-B, HOMA2, and HOMA-IR are represented as functions of BMI and leptin, as shown in the equations:

$$\begin{aligned} \text{HOMA-B (BMI)} &= \text{HOMA-B} + 37 \cdot \text{BMI} \\ \text{HOMA2 (BMI)} &= \text{HOMA2} + 24 \cdot \text{BMI} \\ \text{HOMA-IR (BMI)} &= k_{\text{BMI}} \cdot \text{HOMA-IR} \\ \text{HOMA-IR (L}_0) &= \log(L_0) \cdot \text{HOMA-IR} \\ \text{HOMA-IR (BMI, L}_0) &= k_{\text{BMI}} \cdot \log(L_0) \cdot \text{HOMA-IR} \end{aligned}$$

where L_0 is fasting leptin in ng/mL . In order to establish a closer association with ISI, BMI is incorporated into HOMA-B and HOMA2 calculations by applying a scaling factor, and the resulting values are analyzed to determine their correlation with ISI. Through a systematic evaluation of scaling factor




Fig. 3: Variation of scaling factor used in revised HOMA-B and HOMA2 wrt correlation with ISI

values, the optimal scaling factor, which exhibits the highest correlation with

the ISI, is identified (as shown in Fig. 3). This iterative approach ensures that the scaling factor chosen is the minimum value that maximizes the required correlation. The HOMA-IR index is enhanced by incorporating k_{BMI} and L_0 as separate variables, as well as by considering their combined effect. The correlation between the augmented HOMA-IR index and DI_o is also measured in each case to assess their relationship. By incorporating BMI and fasting leptin values into these indices, clinicians and researchers can gain insights into the combined effects of insulin secretion, insulin resistance, and obesity on T2DM.




Fig. 4: Simulation results sample showing glucose, insulin and leptin concentrations for subjects

6 Results and validation

This section presents the parameter estimation results of the leptin model, along with its analysis and validation. The estimated parameters provide valuable insights into the dynamics of glucose, insulin, and leptin concentrations in IG regulatory system, and validation with data ensures the reliability of *leptin* model.

Results of Parameter Estimation

The model is estimated for parameter values and the resulting simulation closely matches with the observed data. A total of nine parameters are estimated out of the 24-time point data for each subject. Five new parameters - g_i, k_1, k_b, k_6 and k_i of *leptin* model and four parameters - k_1, k_2, k_3 and k_4 of the *base* model are estimated using the Nelder-Mead optimisation method. The parameter ranges are determined based on sensitivity analysis described




Fig. 5: Glucose, insulin, and leptin concentration range for all study participants ($n=38$) for 2-h OGTT. Median glucose, insulin, and leptin concentrations from data (dashed green line) and simulation of *leptin* model (blue line) for a BMI = 25.

in section 4. The parameter description, values, coefficient of variation (CV), and units are described in Table 2. The parameters of the R_a model for glucose absorption, k_{max} , k_{min} , k_{abs} and f are taken from literature[13]. Few parameters of the *leptin* model are calculated based on known relationships or processes. As BMI is usually in the range 18-32, the parameter b_m in k_{BMI} (Eqn 6) is fixed at 21 as the short range of the logistic function gives the effect of BMI adequately. This is the calculated average value of estimated b_m across all the subjects. The parameter k_5 , which is the rate constant for leptin degradation, is found to have a half-life of 26 min [35], and the value is fixed at 0.03. The simulation results of two sample subjects are shown in Fig. 4. The *leptin* model captures the observed time point measurements of leptin along with insulin and glucose. The model effectively captures the relationship between insulin and leptin, wherein an increase in insulin level leads to a decrease in leptin level. This agreement between the model predictions and observed behaviour highlights the ability of the model to represent the regulation between insulin and leptin accurately. CV is calculated to express the relative variability in the parameters. For instance, a CV value of k_b exhibits less variability and more precision, whereas k_l indicates a higher CV which attributes to the range of BMI in subjects (Table 2).

The timepoint measures of glucose, insulin and leptin from dataset-II, along with their median values, are shown in Fig. 5. The simulation result of *leptin* model is also shown to compare it with the median data. In the insulin graph, the simulation shift observed in the farther time points are within the variation of insulin, and for glucose and leptin, the variation is not profound

Results of Parameter Sensitivity Analysis

The newly introduced parameters are sensitive to the observables highlighting the positive aspects of the current model. Sensitivity analysis is done on five parameters k_l , k_b , g_l , k_6 and k_i in *leptin* model, considering a $\pm 30\%$ variation with respect to glucose, insulin, and leptin, and the results are shown in Fig. 2. The parameter g_l is highly sensitive to glucose and insulin whereas less sensitive to leptin which implies the ability of leptin to lower blood glucose levels impacts model behavior significantly. This variation in g_l analysis helps in incorporating adequate ranges for g_l . Insulin concentration is affected by k_6 ,

Indices	ISI
HOMA-B	0.299
HOMA2	0.306
HOMA-B (BMI)	0.467
HOMA2 (BMI)	0.469

(a)

Indices	DI _o
HOMA-IR	0.707
HOMA-IR (L ₀)	0.718
HOMA-IR (BMI)	0.733
HOMA-IR (L ₀ ,BMI)	0.735

(b)

Table 3: (a) Correlation of ISI to HOMA-B and HOMA2 and their revisions (b) Correlation of DI_o to HOMA-IR and revised HOMA-IR

and is moderately sensitive to the inhibitory action of leptin on insulin. k_b is highly sensitive to insulin, glucose, and leptin, emphasizing the role of BMI in the *leptin* model. k_l and k_i are related to the insulin action in the production of leptin and are less sensitive to insulin giving only a small boost in insulin concentration.

Validation of the augmented model and parameters

To evaluate whether the developed *leptin* model is capable of capturing the underlying dynamics of the insulin-glucose system, model validation is performed. The newly introduced parameter values are taken from the augmented model, and simulations are run for all the subjects. The BMI value is made a parameter for this simulation, and the estimated average is 24.6. Other parameter values are taken from literature as given in Table 2. The simulations performed with the *leptin* model demonstrated a better fit to the observed data points when compared to the *base* model. Sample simulation results of the *base* model and *leptin* model using dataset-II are shown in Fig 6. The simulated behavior of leptin is obtained, revealing a pattern that closely resembles the results previously observed for dataset-I. To assess the statistical significance of the differences, a Chi-square goodness of fit test ($\alpha = 0.05$) was performed on the simulated and observed data. The analysis revealed a statistically significant result of p-values with 74% good fits using the *leptin* model compared to 62% good fits using the *base* model.

The *leptin* model is also validated using dataset-I without considering leptin values and the fittings were found to be better. A sample simulation results of the *base* model and *leptin* model using dataset-I are shown in Fig 7.

Results of revised OGTT indices

The correlation values between indices are shown in Table. 3. The inclusion of BMI in HOMA-B and HOMA2 exhibits a better correlation with ISI with coefficients of 0.467 and 0.469, respectively. This observation suggests that the inclusion of BMI enhances the indices by establishing a closer association with ISI.

When examining the correlation between HOMA-IR and DI, the inclusion of BMI and leptin as separate variables, as well as their combined effect,




Fig. 6: Plots of sample subjects showing glucose and insulin (for 75g glucose) for *base* model and *leptin* model using dataset-I

resulted in slightly higher correlation values compared to the existing correlation between these factors. This suggests that BMI and leptin contribute to the relationship between HOMA-IR and DI, and their combined impact further strengthens their association. These revised indices may be used clinically for better assessment of β -cell function and insulin resistance.

7 Discussion

The objective of this work is to augment the existing mathematical model of IG regulatory system to accommodate the role of leptin and BMI. Parameters for the *leptin* model are estimated using the observed data of glucose, insulin and leptin for individuals with T2DM. The simulating results and the observed data have a statistically significant Chi-square fit of 74%. As leptin is involved in gluoregulatory actions, predicting its behaviour through the *leptin* model can help in developing targeted interventions and therapies for managing and treating T2DM taking into account obesity-related issues. By influencing insulin secretion and sensitivity, leptin affects glucose metabolism and overall glycemic control in individuals with T2DM. Leptin is reported to have potent anti-diabetic actions independently of its effects on body weight




Fig. 7: Plots of sample subjects showing glucose and insulin (for 25g glucose) for *base* model and *leptin* model using dataset-II

and food intake [38]. These anti-diabetic effects of leptin can be explored and used in leptin therapy for the treatment of T2DM [38]. Further, long-term leptin-replacement therapy can significantly improve glycemic control and insulin sensitivity in patients with severe IR [39]. The new model can predict leptin behaviour in association with insulin and glucose concentrations using clinically significant parameters. A personalised treatment approach by integrating leptin behaviour may lead to more effective and targeted treatments for metabolic conditions.

Revised OGTT indices (HOMA-B (BMI), HOMA2 (BMI), HOMA-IR (BMI), HOMA-IR (L_0), HOMA-IR (BMI, L_0)) have been proposed. These can aid in better insulin dosage estimation. The effect of the estimated dosage may be better predicted using the *leptin* model. T2DM therapy largely depends on the degree of IR and insulin secretory dysfunction, the contribution of which is associated with obesity. Hence, the inclusion of obesity parameters in assessing IR and β -cell dysfunction is vital in the decision-making process of anti-diabetic therapy. The simple and usable indices proposed in this

work will help decide a precision anti-diabetic therapy for non-obese T2DM patients and may open the door to other possibilities to build more accurate obesity-associated indices for personalised medicine. The claims in the work are based on the available data of 38 subjects. It would be desirable to perform the study on larger data to increase the confidence of the results. A potential future work may be to enhance the presented *leptin* model by incorporating other adipokines (such as adiponectin, adiponectin) that also play a role in the insulin-glucose regulatory system.

8 Conclusion

In this study, the OMM is augmented by incorporating the influence of BMI and leptin levels in the insulin-glucose regulatory system. The model is developed based on several theoretical studies on the association of leptin with insulin and glucose concentrations. The model parameters are estimated and analyzed using the OGTT data collected in a clinical setting. The new model offers valuable insights into the working of the insulin-glucose regulatory system taking into account the obesity of the subject and uncovering related risk factors involved in T2DM. This seems to be the first attempt to model the role of obesity indicators leptin and BMI in glucose regulation using ordinary differential equations (ODE). The revised OGTT indices, with the inclusion of obesity parameters, hold the potential to aid in determining precise anti-diabetic therapies for T2DM. Simulation results from the augmented model with the identified parameters have a good match with the observed data of insulin, glucose, and leptin. The results presented in this work are based on limited available data. It would be desirable to reinforce those by extending the study to larger data.

Declaration of Competing Interest

The authors declare that there are no conflicts of interest.

Acknowledgement

The authors gratefully thank the associates of K V Venkatesh for collecting the insulin-glucose time series data. This work was partly funded by MoE, Government of India.

Data Availability

The code and data used in the current work are available from the corresponding author upon reasonable request.

References

- [1] Galicia-Garcia, U., et al.: Pathophysiology of type 2 diabetes mellitus. *Int. J. Mol. Sci.* **21**(17), 6275 (2020)
- [2] Sarkar, J., Maity, S.K., Sen, A., Nargis, T., Ray, D., Chakrabarti, P.: Impaired compensatory hyperinsulinemia among nonobese type 2 diabetes patients: a cross-sectional study. *Ther. Adv. Endocrinol. Metab.* **10**, 2042018819889024 (2019)
- [3] Aravindakshan, M.R., Maity, S.K., Paul, A., Chakrabarti, P., Mandal, C., Sarkar, J.: Distinct pathoclinical clusters among patients with uncontrolled type 2 diabetes: results from a prospective study in rural india. *BMJ Open Diabetes Research & Care* **10**(1), 002654 (2022). <https://doi.org/10.1136/bmjdr-2021-002654>
- [4] Barnes, A.S.: The epidemic of obesity and diabetes: trends and treatments. *Tex. Heart Inst. J.* **38**(2), 142–144 (2011)
- [5] Meek, T.H., Morton, G.J.: Leptin, diabetes, and the brain. *Indian J. Endocrinol. Metab.* **16**(Suppl 3), 534–42 (2012)
- [6] Martins, M.d.C., Lima Faleiro, L., Fonseca, A.: Relationship between leptin and body mass and metabolic syndrome in an adult population. *Rev. Port. Cardiol. (Engl. Ed.)* **31**(11), 711–719 (2012)
- [7] Paz-Filho, G., Mastronardi, C., Wong, M.-L., Licinio, J.: Leptin therapy, insulin sensitivity, and glucose homeostasis. *Indian J Endocrinol Metab.*, 549–555 (2012). <https://doi.org/10.4103/2230-8210.105571>
- [8] German, J.P., et al.: Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. *Diabetes* **59**(7), 1626–1634 (2010)
- [9] Hamou-Maamar, M., Belhamiti, O.: Leptin effect’s on glucose and insulin kinetics: A mathematical model. *Communications in Nonlinear Science and Numerical Simulation* **113**, 106591 (2022). <https://doi.org/10.1016/j.cnsns.2022.106591>
- [10] Hassell Sweatman, C.Z.W.: Mathematical model of diabetes and lipid metabolism linked to diet, leptin sensitivity, insulin sensitivity and vldltg clearance predicts paths to health and type ii diabetes. *Journal of Theoretical Biology* **486**, 110037 (2020). <https://doi.org/10.1016/j.jtbi.2019.110037>
- [11] Kadota, R., Sugita, K., Uchida, K., Yamada, H., Yamashita, M., Kimura, H.: A mathematical model of type 1 diabetes involving leptin effects on glucose metabolism. *Journal of Theoretical Biology* **456**, 213–223 (2018).

<https://doi.org/10.1016/j.jtbi.2018.08.008>

- [12] Dalla Man, C., Caumo, A., Cobelli, C.: The oral glucose minimal model: Estimation of insulin sensitivity from a meal test. *IEEE Transactions on Biomedical Engineering* **49**(5), 419–429 (2002). <https://doi.org/10.1109/10.995680>
- [13] Man, C.D., Camilleri, M., Cobelli, C.: A system model of oral glucose absorption: Validation on gold standard data. *IEEE Transactions on Biomedical Engineering* **53**(12), 2472–2478 (2006). <https://doi.org/10.1109/tbme.2006.883792>
- [14] Diabetes & Prediabetes Tests. US Department of Health and Human Services (2020). <https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/diabetes/diabetes-prediabetes?dkrd=hisce0124> Accessed 2010-09-30
- [15] Bergman, R.N.: The minimal model of glucose regulation: A biography. In: *Advances in Experimental Medicine and Biology*. Advances in experimental medicine and biology, pp. 1–19. Springer, Boston, MA (2003)
- [16] Hovorka, R., et al.: Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. *Physiological Measurement* **25**(4), 905–920 (2004). <https://doi.org/10.1088/0967-3334/25/4/010>
- [17] Sturis, J., Polonsky, K.S., Mosekilde, E., Van Cauter, E.: Computer model for mechanisms underlying ultradian oscillations of insulin and glucose. *American Journal of Physiology - Endocrinology and Metabolism* **260**(5 23-5) (1991). <https://doi.org/10.1152/ajpendo.1991.260.5.e801>
- [18] Bergman, R.N.: Origins and history of the minimal model of glucose regulation. *Front. Endocrinol. (Lausanne)* **11**, 583016 (2020)
- [19] Jin, J., Li, J., Xu, R., Yu, L., Jin, Z.: A novel IVGTT model including interstitial insulin. *Math. Appl. Sci. Eng.* **4**(1), 12–29 (2023)
- [20] Yadav, A., Jyoti, P., Jain, S.K., Bhattacharjee, J.: Correlation of adiponectin and leptin with insulin resistance: a pilot study in healthy north indian population. *Indian J. Clin. Biochem.* **26**(2), 193–196 (2011)
- [21] Cammisotto, P.G., Bendayan, M.: Leptin secretion by white adipose tissue and gastric mucosa. *Histol. Histopathol.* **22**(2), 199–210 (2007)
- [22] Homa calculator. Radcliffe Department of Medicine (2023). <https://www.rdm.ox.ac.uk/about/our-clinical-facilities-and-mrc-units/DTU/software/homa>

- [23] Utzschneider, K.M., et al.: Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. *Diabetes Care* **32**(2), 335–341 (2009)
- [24] Schittkowski, K.: Parameter estimation in dynamic systems. In: *Applied Optimization*, pp. 183–204. Springer, Boston, MA (2000)
- [25] Guedj, J., Thiébaud, R., Commenges, D.: Maximum likelihood estimation in dynamical models of hiv. *Biometrics* **63**(4), 1198–1206 (2007)
- [26] Singer, S., Nelder, J.: Nelder-mead algorithm. *Scholarpedia* **4**(7), 2928 (2009)
- [27] García-Portugués, E.: Notes for Predictive Modeling, (2022). Version 5.9.10. ISBN 978-84-09-29679-8. <https://bookdown.org/egarpor/PM-UC3M/>
- [28] Akman, O., Schaefer, E.: An evolutionary computing approach for parameter estimation investigation of a model for cholera. *J. Biol. Dyn.* **9**(1), 147–158 (2015)
- [29] D'souza, A.M., Neumann, U.H., Glavas, M.M., Kieffer, T.J.: The glucoregulatory actions of leptin. *Molecular Metabolism* **6**(9), 1052–1065 (2017). <https://doi.org/10.1016/j.molmet.2017.04.011>
- [30] Cignarelli, A., Genchi, V.A., Perrini, S., Natalicchio, A., Laviola, L., Giorgino, F.: Insulin and insulin receptors in adipose tissue development. *Int. J. Mol. Sci.* **20**(3), 759 (2019)
- [31] Hoffman, R.M., Boston, R.C., Stefanovski, D., Kronfeld, D.S., Harris, P.A.: Obesity and diet affect glucose dynamics and insulin sensitivity in thoroughbred geldings. *J. Anim. Sci.* **81**(9), 2333–2342 (2003)
- [32] Paul, R.F., Hassan, M., Nazar, H.S., Gillani, S., Afzal, N., Qayyum, I.: Effect of body mass index on serum leptin levels. *J. Ayub Med. Coll. Abbottabad* **23**(3), 40–43 (2011)
- [33] German, J.P., et al.: Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. *Endocrinology* **152**(2), 394–404 (2011). <https://doi.org/10.1210/en.2010-0890>
- [34] Dawson, J.: BIOC*2580: Introduction to Biochemistry, (2021)
- [35] Morath, V., et al.: PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy. *Mol. Pharm.* **12**(5), 1431–1442 (2015)
- [36] Virtanen, P., Gommers, R., Oliphant, T.E., et al.: SciPy 1.0: Fundamental

- Algorithms for Scientific Computing in Python. *Nature Methods* **17**, 261–272 (2020). <https://doi.org/10.1038/s41592-019-0686-2>
- [37] Newville, M.e.a.: lmfit/lmfit-py: 1.2.1 (2023). <https://doi.org/10.5281/ZENODO.7887568>
- [38] Coppari, R., Bjørbæk, C.: Leptin revisited: its mechanism of action and potential for treating diabetes. *Nat. Rev. Drug Discov.* **11**(9), 692–708 (2012)
- [39] Paz-Filho, G., et al.: Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. *Am. J. Physiol. Endocrinol. Metab.* **295**(6), 1401–8 (2008)